Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ-062, also known as bofu-tsusho-san or TJ-62, is a traditional Japanese Kampo medicine formulation under investigation for its anti-obesity and thermogenic effects. It is a small molecule drug composed of multiple herbal extracts. Preclinical studies in mice have shown that TJ-062 activates brown adipose tissue (BAT) thermogenesis and inhibits phosphodiesterase activity, leading to increased energy expenditure and reduced body weight without affecting food intake. The mechanism appears to involve enhanced GDP binding in BAT and inhibition of phosphodiesterase similar to caffeine. The product contains active components such as 1-E (likely ephedrine-type alkaloid) and d-PE (possibly p-synephrine or related compound), but the full composition includes several herbal extracts typical of Kampo formulas[1]. Developed by Shanghai Tuojie Biotechnology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TJ-062.